Wegovy is the brand name for semaglutide when it’s prescribed for weight loss. Semaglutide is also the active ingredient in Ozempic — the difference is the licence and intended use: Ozempic is licensed for diabetes management, while Wegovy is licensed for weight management in eligible patients.
Semaglutide is a GLP-1 receptor agonist. GLP-1 medicines work by mimicking a hormone called GLP-1 that the body naturally releases after eating. This can help patients feel fuller for longer and reduce appetite and cravings.
Wegovy at a glance
Up to ~15% weight loss after the first year (varies by individual and depends on dose, adherence and lifestyle changes)
Once-weekly injection
Maintenance dose: 2.4mg weekly (for patients who titrate up and tolerate it) and new 7.2mg dose for maintenance
Typical age range used in services: 18–85 (subject to clinical assessment and eligibility)
Heart health benefits: Wegovy has evidence of cardiovascular benefit in certain patient groups (eligibility and relevance depend on the individual — prescriber guidance applies)
Comments
0 comments
Article is closed for comments.